Keros starts Phase 2 trial of Rinvatercept for Duchenne muscular dystrophy
Keros Therapeutics has dosed the first patient in a Phase 2 trial of Rinvatercept targeting Duchenne muscular dystrophy. As a clinical-stage biopharmaceutical company with no current drug products on the market, this trial initiation is a significant milestone for its neuromuscular development strategy.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed